ACM
PLRX icon

Altium Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Altium Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$1.93M – 102
2022
Q4 		$1.93M Sell
100,000
-115,000
-53% -$2.4M 0.98% 37
2022
Q3 		$4.49M Buy
+215,000
New +$4.11M 1.65% 14

Other funds holding PLRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Altium Capital Management's PLRX Position: Q1 2023 in Review

Altium Capital Management sold out of Pliant Therapeutics (PLRX) in Q1 2023, closing a stake of 100,000 shares — an estimated $1.93M sold.

Altium Capital Management first reported a position in PLRX in Q3 2022 and held it in 2 quarters. The position peaked at $4.49M in Q3 2022. 143 funds tracked by Wall St. Rank hold PLRX as of Q1 2023.

  • Altium Capital Management reported no remaining Pliant Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Altium Capital Management sold 100,000 Pliant Therapeutics shares in Q1 2023, an estimated $1.93M.
  • Altium Capital Management first reported a position in Pliant Therapeutics in Q3 2022 and held it in 2 quarters.
  • Altium Capital Management's Pliant Therapeutics position peaked at $4.49M in Q3 2022.
  • 143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2023.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.